GSK has been in the news frequently over the past three years with respect to changes in its incentive compensation program.
In June 2010, GSK announced that bonuses for salespeople in the U.S. who work directly with HCPs would no longer be based on individual achievement of sales targets, but will be based primarily on the service they deliver to customers. Bonuses would be determined, in part, by customer feedback, and by a sales professional’s adherence to the company values of transparency, integrity, respect and patient-focus. In July 2012, GSK entered a Corporate Integrity Agreement with the Office of the Inspector General of the US government, stating in part that GSK will not provide financial reward for its salespeople based upon the volume of sales of GSK products within a given employee’s own territory. Most recently, a December 2013 article in The New York Times described that GSK is extending the incentive compensation provisions to the rest of its global business by 2015.